TLN1 Antibody

What is TLN1 and why is it significant in cell biology research?

TLN1 (Talin 1) is a large cytoskeletal protein (approximately 270 kDa) that functions as a critical mechanical link between integrins and the actin cytoskeleton. It contains a FERM domain comprising F0, F1, F2, and F3 subdomains, with the F3 domain being crucial for integrin binding and activation . TLN1 is concentrated at regions of cell-substratum contact and, in lymphocytes, at cell-cell contacts, where it mediates connections between major cytoskeletal structures and the plasma membrane . The protein's mechanosensitive properties enable it to transduce physical forces across the cell membrane, regulating focal adhesion (FA) dynamics, cell adhesion, migration, and signal transduction . TLN1's significance extends to pathological contexts, as its dysregulation has been implicated in cancer progression, particularly in promoting metastasis through altered cell adhesion and enhanced invasive capacity .

How do I select the appropriate TLN1 antibody for my specific experimental application?

Selection of an appropriate TLN1 antibody should be guided by several key considerations:

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, IHC, ICC/IF, IP, Flow Cytometry). For example, Boster Bio's Anti-Talin 1/TLN1 Antibody (A02859-2) is validated for multiple applications including ELISA, Flow Cytometry, IF, IHC, ICC, and WB .

• Species reactivity: Ensure the antibody recognizes TLN1 in your experimental species. Many antibodies, such as GeneTex's anti-Talin-1 antibody, react with human and mouse samples, while others like MyBioSource's Talin-1 Polyclonal Antibody also detect rat TLN1 .

• Epitope specificity: Consider whether you need an antibody that specifically recognizes TLN1 or one that detects both TLN1 and TLN2 (e.g., Abcam's mouse monoclonal antibody [8D4]) .

• Validated literature: Review citation records to confirm successful use in similar experimental systems. For instance, the Abcam ab11188 antibody has been cited in at least 16 publications .

• Format requirements: Determine if you need unconjugated antibodies or specific conjugates (biotin, Cy3, Dylight488, etc.) based on your detection method .

For quantitative applications like Western blotting, antibodies designated as high-affinity or "premium" (such as Boster's Picoband® designation) may provide superior signal-to-noise ratios .

What are the structural and functional domains of TLN1 that antibodies typically target?

TLN1 contains distinct structural domains that serve as potential antibody targets:

Domain Structure of TLN1:

The F3 subdomain, which contains the S1 and S2 chains of the phosphotyrosine-binding (PTB) domain, is particularly significant as it mediates critical interactions with integrin β tails and is essential for integrin activation . This domain is often targeted for antibodies designed to block TLN1-integrin interactions, as demonstrated in research identifying the small molecule C67399 that interrupts TLN1-integrin β1 binding at this interface .

Commercial antibodies frequently target epitopes within either the head or rod domains, with some specifically designed to recognize the functionally critical F3 domain for studies investigating integrin-mediated adhesion dynamics .

What are the optimal protocols for using TLN1 antibodies in Western blot applications?

Optimized Western Blot Protocol for TLN1 Detection:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors for cell lysis (as used in studies with MDA-MB-231 cells)

  • Determine protein concentration using BCA assay

  • Load 30-40 μg of protein per lane (optimal for TLN1 detection)

• Gel selection and separation:

  • Use low percentage (5-8%) SDS-PAGE gels or gradient gels (5-20%) to properly resolve the high molecular weight TLN1 (270 kDa)

  • Run stacking gel at 70V and resolving gel at 90V for 2-3 hours for optimal separation

• Transfer conditions:

  • Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes (longer transfer times improve efficiency for large proteins)

  • Verify transfer efficiency with Ponceau S staining before proceeding

• Blocking and antibody incubation:

  • Block membrane with 5% non-fat milk or 5% BSA in TBST for 1-1.5 hours at room temperature

  • Incubate with primary TLN1 antibody at 0.5-2 μg/ml concentration overnight at 4°C

  • Wash thoroughly with TBST (3 times, 5 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody (typically 1:5000-1:10,000 dilution) for 1-1.5 hours at room temperature

• Detection:

  • Develop using enhanced chemiluminescence (ECL) reagents

  • Expected band size for TLN1 is approximately 270 kDa

This protocol has been successfully used to detect TLN1 in various cell lines including HeLa, HepG2, Raji, 293T, rat C6, and mouse lung tissue lysates .

How can I effectively use TLN1 antibodies for immunohistochemistry in cancer tissue samples?

Optimized IHC Protocol for TLN1 Detection in Cancer Tissues:

• Tissue preparation and sectioning:

  • Use paraffin-embedded tissue sections (4-6 μm thickness)

  • Mount sections on positively charged slides

• Antigen retrieval (critical for TLN1 detection):

  • Perform heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

  • This specific buffer condition has been validated for optimal TLN1 epitope exposure in multiple cancer tissues

• Blocking and antibody incubation:

  • Block with 10% goat serum to reduce background staining

  • Incubate with anti-TLN1 antibody at 2 μg/ml concentration overnight at 4°C

  • For visualization, use peroxidase-conjugated secondary antibody (30 minutes at 37°C) followed by DAB as the chromogen

• Counterstaining and evaluation:

  • Counterstain with hematoxylin to visualize tissue architecture

  • Evaluate TLN1 expression patterns in membrane and cytoplasm, as TLN1 is typically localized in both compartments

This protocol has been successfully applied to detect TLN1 in various cancer tissues including bladder urothelial carcinoma, lung cancer, and testicular germ cell tumors . Studies have demonstrated that TLN1 is ubiquitously expressed in the membrane and cytoplasm of both paraneoplastic and tumor tissues, with significantly higher expression levels observed in tumor samples compared to adjacent non-tumor tissues in triple-negative breast cancer .

What methods are recommended for analyzing TLN1-integrin interactions using antibody-based approaches?

Co-immunoprecipitation (Co-IP) and proximity ligation assays are powerful methods for studying TLN1-integrin interactions:

Co-immunoprecipitation Protocol for TLN1-Integrin β1 Interaction:

• Cell lysate preparation:

  • Lyse cells (1 × 10^7) in cold RIPA buffer containing protease inhibitors

  • Remove cell debris by centrifugation

  • Determine protein concentration (typically 50 μg/tube is sufficient)

• Immunoprecipitation:

  • Incubate cell lysates with anti-TLN1 or anti-integrin β1 antibody (2 μg) overnight at 4°C with gentle agitation

  • Add 50 μl of protein A/G agarose beads and incubate for 4 hours at 4°C

  • Collect immunocomplexes by centrifugation (700 g, 4°C, 5 minutes)

  • Wash thoroughly to remove non-specific binding

• Elution and analysis:

  • Elute bound proteins by heating at 100°C for 5 minutes in sample buffer

  • Analyze by Western blotting using antibodies against the interacting partner

  • For TLN1-integrin β1 interaction, probe with anti-integrin β1 after TLN1 immunoprecipitation or vice versa

This approach has been successfully used to investigate TLN1-integrin β1 interactions in MDA-MB-231 triple-negative breast cancer cells, revealing crucial insights into the mechanism of cancer cell adhesion and metastasis .

How can TLN1 antibodies be used to investigate focal adhesion dynamics and cell migration?

TLN1 antibodies can be utilized in several sophisticated approaches to study focal adhesion (FA) dynamics and cell migration:

• Immunofluorescence microscopy for FA visualization:

  • Fix cells using 4% paraformaldehyde to preserve FA structures

  • Permeabilize with 0.5% Triton X-100 to allow antibody access to intracellular TLN1

  • Block with appropriate serum and incubate with TLN1 antibody

  • Co-stain with phalloidin to visualize actin cytoskeleton and DAPI for nuclei

  • This approach revealed that TLN1 silencing leads to significantly shorter cells, fewer FAs, predominant localization of FAs on the cell membrane, and significant thickening of the actin cortex

• Live-cell imaging with fluorescently tagged TLN1 antibody fragments:

  • Use Fab fragments conjugated to fluorophores for dynamic studies

  • Combine with TIRF (Total Internal Reflection Fluorescence) microscopy for enhanced resolution of FA dynamics at the cell surface

• Quantitative analysis of FA parameters:

  • Measure FA number, size, distribution, and turnover rates

  • Example parameters from TLN1 studies include:

These approaches have demonstrated that TLN1 is crucial for FA dynamic formation, adhesion, and invasion in cancer cells, particularly in triple-negative breast cancer, where silencing TLN1 significantly attenuates integrin β1 signaling and impairs cell migration and invasion .

What are the methodological considerations for using TLN1 antibodies to evaluate its role as a prognostic biomarker in cancer?

Utilizing TLN1 antibodies for prognostic biomarker evaluation requires careful methodological considerations:

• Validation across multiple cohorts:

  • Validate findings in independent patient cohorts using the same antibody and protocol

  • For example, TLN1 upregulation has been consistently associated with poor prognosis across multiple cancer types including TNBC, prostate cancer, liver cancer, and AML

These approaches have demonstrated TLN1's value as a prognostic biomarker in several cancer types, with its expression correlating with disease stage, metastatic potential, and patient survival outcomes .

How can TLN1 antibodies be employed in studies targeting the TLN1-integrin axis for cancer therapy?

TLN1 antibodies serve as crucial tools in developing and evaluating therapeutic strategies targeting the TLN1-integrin axis:

• Target validation studies:

  • Use TLN1 antibodies to confirm protein expression in patient-derived samples

  • Employ immunoprecipitation with TLN1 antibodies to verify integrin interactions in various cancer models

  • Researchers have validated TLN1/integrin β1 signaling as crucial for malignant behaviors in TNBC cells, identifying it as a promising therapeutic target

• Screening assays for TLN1-integrin interaction inhibitors:

  • Develop competitive binding assays using labeled TLN1 antibodies

  • Create ELISA-based screening platforms with immobilized TLN1 or integrin proteins

  • This approach led to the identification of small molecule C67399 that blocks TLN1-integrin β1 interaction

• Mechanism of action studies:

  • Utilize TLN1 antibodies in combination with:

    • Phospho-specific antibodies for downstream signaling (FAK, AKT)

    • EMT markers (E-cadherin, N-cadherin, vimentin)

    • Cellular phenotype assessment (proliferation, migration, invasion)

  • Research has shown that disrupting TLN1-integrin β1 binding with C67399:

    • Significantly reduced cell adhesion, migration, and invasion

    • Decreased levels of phosphorylated FAK and AKT

    • Inhibited tumor growth and metastasis in vivo

• Structure-guided drug design:

  • Use epitope-specific TLN1 antibodies to identify critical binding interfaces

  • Research targeting the F3 domain of TLN1 (particularly the S1 and S2 chains of the PTB domain) has proven successful in developing inhibitors of TLN1-integrin interactions

This multi-faceted approach has led to significant advances in targeting the TLN1-integrin axis, with promising preclinical results showing that disrupting this interaction can effectively inhibit tumor growth and metastasis in triple-negative breast cancer models .

What are common challenges in detecting TLN1 by Western blot and how can they be addressed?

Challenge 1: Poor detection of the high molecular weight TLN1 (270 kDa)

Challenge 2: High background or non-specific bands

Challenge 3: Variable results across different cell/tissue types

Researchers have successfully detected TLN1 in various cell lines including HeLa, HepG2, Raji, 293T, rat C6, and mouse lung tissue using optimized Western blot protocols with anti-TLN1 antibodies at 0.5 μg/mL concentration .

How should researchers interpret variations in TLN1 localization patterns observed in immunofluorescence studies?

Interpreting TLN1 localization patterns requires understanding its context-dependent distribution and function:

Common TLN1 Localization Patterns and Their Interpretation:

• Focal adhesion localization:

  • Appearance: Distinct punctate structures at cell periphery and beneath the cell body

  • Interpretation: Active involvement in cell-ECM adhesion and integrin activation

  • Context: Typical in adherent cells on ECM substrates

  • Verification: Co-localization with other FA proteins (paxillin, vinculin, FAK)

• Membrane and cytoplasmic distribution:

  • Appearance: Diffuse cytoplasmic and membrane staining

  • Interpretation: Reserve pool of inactive TLN1 or potential non-adhesion roles

  • Context: Common in many cell types, including cancer cells

  • Verification: Compare with activation state markers or membrane fractionation

• Altered distribution in cancer cells:

  • Appearance: Enhanced membrane localization or altered FA patterns

  • Interpretation: Associated with increased metastatic potential

  • Context: Observed in TNBC and other aggressive cancers

  • Evidence: Research has shown ubiquitous expression of TLN1 in the membrane and cytoplasm of both paraneoplastic and tumor tissues, with significantly higher levels in TNBC tumors

• Response to TLN1 manipulation:

  • Appearance: After TLN1 silencing, fewer FAs with predominant membrane localization

  • Interpretation: Defects in FA maturation and turnover

  • Context: Experimental manipulation in cancer cell lines

  • Evidence: Silencing TLN1 in MDA-MB-231 cells led to significantly shorter cells with fewer FAs, predominantly localized on the cell membrane

• Co-localization with integrins:

  • Appearance: Overlapping signals between TLN1 and integrin β1

  • Interpretation: Active TLN1-integrin complexes

  • Context: Critical for evaluating TLN1 functional status

  • Application: Used to assess effects of compounds like C67399 that block TLN1-integrin interactions

How can researchers validate the specificity of TLN1 antibodies and distinguish between TLN1 and TLN2 in their experiments?

Validating TLN1 antibody specificity and distinguishing between TLN1 and TLN2 requires systematic approaches:

• Genetic validation approaches:

  • CRISPR/Cas9 knockout of TLN1: Create TLN1-null cell lines using sequences like 5′-GCAGTGAAAGATGTAGCCAAA-3′ that have been validated for TLN1 knockdown

  • siRNA/shRNA knockdown: Use TLN1-specific shRNA sequences to validate antibody specificity through reduced signal in Western blot or immunofluorescence

  • Overexpression systems: Transfect cells with tagged TLN1 constructs to confirm antibody detection of the overexpressed protein

• Biochemical validation methods:

  • Western blot analysis: Compare antibody reactivity using:

    • Tissues from TLN1 and TLN2 knockout models

    • Cell lines with known differential expression of TLN1 vs. TLN2

    • Recombinant TLN1 and TLN2 proteins as controls

  • Mass spectrometry: Confirm antibody-captured proteins by immunoprecipitation followed by MS analysis

• TLN1 vs. TLN2 distinction strategies:

  • Use isoform-specific antibodies: Select antibodies targeting non-homologous regions between TLN1 and TLN2

  • Perform parallel staining: Use verified TLN1 and TLN2-specific antibodies on adjacent sections

  • Expression pattern analysis: Leverage tissue-specific expression differences (TLN1 is more ubiquitous while TLN2 has more restricted expression)

• Commercial antibody selection for isoform specificity:

• Control experiments:

  • Include recombinant protein standards when possible

  • Use tissues/cells with known expression patterns as positive and negative controls

  • Perform antibody validation experiments in parallel with experimental samples

These validation approaches ensure experimental results accurately reflect TLN1-specific biology and prevent misinterpretation due to antibody cross-reactivity with TLN2.

How can TLN1 antibodies contribute to understanding the mechanistic role of TLN1 in cancer progression and metastasis?

TLN1 antibodies are instrumental in elucidating the complex mechanisms driving cancer progression and metastasis:

• Mapping TLN1 expression patterns across cancer types:

  • IHC studies using TLN1 antibodies have revealed upregulation in multiple cancers including TNBC, prostate cancer, liver cancer, oral squamous cell carcinoma, and AML

  • In TNBC, TLN1 protein levels were significantly higher in tumor tissues than in para-cancerous tissues, with high expression detected in chest wall recurrence, lymphatic metastasis, and intestinal metastasis

  • These expression patterns provide crucial insights into tissue-specific roles of TLN1 in cancer biology

• Dissecting TLN1-mediated signaling pathways:

  • Antibody-based techniques have demonstrated that TLN1 silencing reduces levels of integrin β1 and phosphorylated AKT and FAK in cancer cells

  • Co-immunoprecipitation studies have identified critical protein-protein interactions in the TLN1 signaling network

  • Enrichment analysis of TLN1-related genes in AML showed associations with neutrophil-mediated immunity, neutrophil activation, and regulation of tyrosine kinase receptor, FLT3, and PIK3/AKT pathways

• Investigating epithelial-mesenchymal transition (EMT):

  • TLN1 antibodies have been used to demonstrate that silencing TLN1 significantly increases expression of epithelial markers (CK18, E-cadherin) while decreasing mesenchymal markers (N-cadherin, vimentin) in TNBC cells

  • This suggests TLN1 promotes cancer progression partly through EMT regulation

• Focal adhesion dynamics and cell migration:

  • Confocal microscopy with TLN1 antibodies revealed that silencing TLN1 leads to significantly shorter cells, fewer focal adhesions, and altered actin cytoskeleton organization

  • These changes correlate with reduced invasion and migration capabilities in cancer cells

• Therapeutic target validation:

  • TLN1 antibodies have facilitated the development and validation of small molecule inhibitors like C67399 that block TLN1-integrin β1 interaction

  • This approach represents a novel therapeutic strategy for cancer treatment, particularly for aggressive cancers like TNBC

These findings collectively demonstrate how TLN1 antibodies have advanced our understanding of TLN1's role in promoting cancer progression through multiple mechanisms including altered cell adhesion, enhanced migration/invasion, EMT induction, and activation of oncogenic signaling pathways.

What emerging technologies are enhancing the utility of TLN1 antibodies in biomedical research?

Several cutting-edge technologies are expanding the applications and improving the performance of TLN1 antibodies in research:

• Single-cell analysis technologies:

  • Single-cell Western blotting allows TLN1 detection with cellular resolution

  • Mass cytometry (CyTOF) can incorporate metal-conjugated TLN1 antibodies for high-dimensional analysis of TLN1 in heterogeneous samples

  • These approaches enable researchers to characterize TLN1 expression at unprecedented resolution in complex tissues

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, PALM, SIM) combined with TLN1 antibodies provides nanoscale visualization of TLN1 localization within focal adhesions

  • Intravital imaging with fluorescently-labeled TLN1 antibody fragments can track TLN1 dynamics in live animal models

  • These technologies have revealed previously undetectable details about TLN1's spatial organization and dynamics

• Proximity labeling approaches:

  • BioID or APEX2 fusion with TLN1 combined with antibody-based detection enables mapping of the TLN1 interactome in living cells

  • Proximity ligation assays with TLN1 antibodies allow visualization of protein-protein interactions in situ

  • These methods have expanded our understanding of TLN1's binding partners and signaling networks

• Antibody engineering advances:

  • Recombinant antibody fragments (Fab, scFv) against TLN1 offer improved tissue penetration and reduced background

  • Site-specific conjugation techniques provide homogeneous antibody reagents with defined label stoichiometry

  • Nanobodies against TLN1 enable new applications due to their small size and stability

• Computational approaches:

  • Virtual screening methods like CSTPPI (computational screening approach by targeting protein-protein binding interface) have been used to identify compounds that block TLN1-integrin β1 interaction

  • This approach led to the discovery of small molecule C67399, which showed promise in inhibiting TNBC cell adhesion, migration, and metastasis

These technological advances are enhancing the spatial and temporal resolution of TLN1 detection, facilitating the discovery of TLN1 interaction partners, and accelerating the development of therapeutic strategies targeting TLN1-mediated processes in disease.

What are the most promising translational applications of TLN1 antibody-based research in clinical oncology?

TLN1 antibody-based research has opened several promising avenues for clinical translation in oncology:

These translational applications highlight how fundamental research using TLN1 antibodies is driving progress toward improving cancer diagnosis, prognosis, and treatment through multiple complementary approaches.